glp-1 agonists vision loss blindness Frontiers GLP-1 Receptor Agonists and Sight-Threatening

Going forward, the trajectory of this market will depend on how effectively stakeholders balance accessibility with safety, innovation with regulation, and affordability with quality

Financial Times reported this week that Lilly and Novo, the manufacturers of all four GLP-1 drugs commonly used for obesity therapy, are spending $3.5 billion this year to purchase smaller companies with promising anti-obesity therapies

The team explored several pathways, including the PI3K/Akt pathway, which affects pancreatic duodenal homeobox 1 (PDX1) and Forkhead box O1 (FoxO1) transcription factors, essential for cell proliferation

And our current thinking is that if someone's developing obesity, particularly moderate to severe obesity in this society, they most likely have a genetic predisposition from our ancestors to put on calories and they don't balance their body fat very well

Whats behind this link